Real world study comparing commonly prescribed COPD medicines shows choice of treatment has impact on patient outcomes
19 March 2013 | By AstraZeneca
PATHOS a real-world retrospective study...
List view / Grid view
19 March 2013 | By AstraZeneca
PATHOS a real-world retrospective study...
19 March 2013 | By Biogen Idec
Patent offers protection until 2028 and strengthens growing product patent portfolio...
19 March 2013 | By Amgen
These are the first Phase 3 results of this novel approach to cancer therapy...
19 March 2013 | By InvivoSciences Inc.
Torrey Pines Institute for Molecular Studies and InvivoSciences collaborate to accelerate drug discovery in cardiac disease...
18 March 2013 | By AstraZeneca
Centres positioned to take better advantage of bioscience clusters...
18 March 2013 | By Novartis
Alcon announces EU approval of Jetrea®, first and only eye drug to treat sight-threatening vitreomacular traction and macular hole...
18 March 2013 | By Roche
The EMA has expanded the approval of Pegasys...
18 March 2013 | By Novo Nordisk
Novo Nordisk announced the headline results from a 56-week, double-blind phase 3a clinical trial...
16 March 2013 | By Daiichi Sankyo
Results of the PRASFIT-ACS study...
15 March 2013 | By Novartis
First filing for LDK378 anticipated in early 2014...
Lonza Walkersville, Inc. and Hyglos GmbH, a German biotech company, announced today that they have reached a mutually beneficial global settlement which includes a license agreement for Hyglos under certain Lonza patents in the area of endotoxin detection.
14 March 2013 | By Pegasus
The EC has approved expanded options for pre-treatment prior to use of QUTENZA...
13 March 2013 | By Novartis
New data will be presented...
13 March 2013 | By Merck
Collaboration to support patient selection for the clinical development of MK-8931, Merck’s lead investigational medicine for AD...
12 March 2013 | By Biogen Idec
“This regulatory submission marks another significant step..."